3-(2,3,4-三甲氧基苯基)丙酸 | 33130-04-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: 3-(2,3,4-三甲氧基苯基)丙酸
• 英文名称: 3-(2,3,4-trimethoxyphenyl)propanoic acid
• CAS: 33130-04-0
• 化学式: C₁₂H₁₆O₅
• mdl: MFCD00002773
• 分子量: 240.256
• InChiKey: QOPNYPCVRBRZOP-UHFFFAOYSA-N

物化性质

• 熔点：
  70-73℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2918990090
• 危险性防范说明：
  P233,P260,P261,P264,P271,P280,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Name:	3-(2 3 4-TRIMETHOXYPHENYL)PROPIONIC ACID 98+% Material Safety Data Sheet
Synonym:	2,3,4-Trimethoxyhydrocinnamic aci
CAS:	33130-04-0

Section 1 - Chemical Product MSDS Name:3-(2 3 4-TRIMETHOXYPHENYL)PROPIONIC ACID 98+% Material Safety Data Sheet
Synonym:2,3,4-Trimethoxyhydrocinnamic aci

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
33130-04-0	3-(2,3,4-TRIMETHOXYPHENYL)PROPIONIC AC		251-389-0

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
The toxicological properties of this material have not been investigated. Use appropriate procedures to prevent opportunities for direct contact with the skin or eyes and to prevent inhalation.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids.
Skin:
Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up, then place into a suitable container for disposal.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Keep container closed when not in use.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate general or local exhaust ventilation to keep airborne concentrations below the permissible exposure limits. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits CAS# 33130-04-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves and clothing to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
Wear a NIOSH/MSHA or European Standard EN 149 approved full-facepiece airline respirator in the positive pressure mode with emergency escape provisions.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Not available.
Color: Not available.
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 70.00 - 73.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H16O5
Molecular Weight: 240.26

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Not available.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 33130-04-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(2,3,4-TRIMETHOXYPHENYL)PROPIONIC ACID, 98+% - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 33130-04-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 33130-04-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 33130-04-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(2,3,4-三甲氧基苯基)丙酸 在 氯化亚砜 、 氯仿 、 alkaline aqueous sodium hypobromite 作用下， 生成 2-(2,3,4-三甲氧基苯基)乙胺
  参考文献：
  名称：

  Slotta; Heller, Chemische Berichte, 1930, vol. 63, p. 3029,3043

  摘要：

  DOI：
• 作为产物：
  描述：

  2,3,4-三甲氧基苯甲醛 在 哌啶 、 吡啶 、 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 23.0~115.0 ℃ 、101.33 kPa 条件下， 反应 29.0h， 生成 3-(2,3,4-三甲氧基苯基)丙酸
  参考文献：
  名称：

  首次全合成外消旋螯合酸

  摘要：

  外消旋螯合酸全合成的关键步骤是铈催化的β-氧代酯的α-羟基化和氰化物催化的各中间产物环转化为δ-内酯结构。

  DOI：

  10.1002/ejoc.202101508

文献信息

• [EN] BROMODOMAIN INHIBITORS<br/>[FR] INHIBITEURS DE BROMODOMAINE
  申请人：ABBVIE INC

  公开号：WO2014206150A1

  公开（公告）日：2014-12-31

  The present invention provides for compounds of formula (I). wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了式（I）的化合物。其中Rx、Ry、Rx1、L1、G1、A1、A2、A3和A4具有规范中定义的任何值，并且其药学上可接受的盐，可用作治疗疾病和病症的药剂，包括炎症性疾病、癌症和艾滋病。还提供了由一种或多种式（I）的化合物组成的药物组合物。
• TUBULIN BINDING AGENTS
  申请人：The Provost, Fellows, Foundation Scholars, & the other Members of Board, of the College of the Holy

  公开号：US20150018566A1

  公开（公告）日：2015-01-15

  The invention provides combretastatin A-4 like compounds that are modified to have enhanced tubulin binding activity and in some embodiments the ability to promote accumulation in the vasculature undergoing angiogenesis (homing activity). The compounds are based on the combretastatin A-4 skeletal structure having a tubulin-binding pharmacophore comprising two fused rings (A and B rings) in which the B ring is substituted with (a) an aromatic ring structure (C ring) and (b) a second substituent/functional group that comes off the B ring. The aromatic ring structure is typically a six membered ring phenolic or aniline structure, or may also be a fused ring structure such as a substituted or unsubstituted naphthalene. The second substituent on the B ring may for example be a substituent which has been found to provide enhanced tubulin binding activity (for example a carbonyl group), or may be a substituent that facilitates functionalisation of the B ring (for example an hydroxyl or amine group), or it may be a binding agent for a target that is preferentially expressed on vasculature undergoing angiogenesis, and not expressed on quiescent vasculature.

  该发明提供了类似于康柏他定A-4的化合物，经过改良以增强微管结合活性，在某些实施例中还具有促进在进行血管生成的血管系统中积聚（归巢活性）的能力。这些化合物基于康柏他定A-4的骨架结构，其具有一个微管结合药效团，包括两个融合环（A环和B环），其中B环被取代为（a）芳香环结构（C环）和（b）从B环上脱落的第二取代基/官能团。芳香环结构通常是一个六元环酚或苯胺结构，也可以是一个融合环结构，如取代或未取代的萘。B环上的第二取代基可以是已知可提供增强微管结合活性的取代基（例如酰基），也可以是促进B环官能化的取代基（例如羟基或胺基），或者可以是一种针对在进行血管生成的血管系统上优先表达而在静止血管系统上不表达的靶标的结合剂。
• Synthesis, biological evaluation and mechanism study of chalcone analogues as novel anti-cancer agents
  作者：Jie Chen、Jun Yan、Jinhui Hu、Yanqing Pang、Ling Huang、Xingshu Li

  DOI：10.1039/c5ra14888j

  日期：——

  A series of novel chalcone analogues were designed, synthesized and evaluated as anticancer agents. The results of antiproliferative activity tests showed that most of the analogues exhibited moderate to very good antiproliferative activities with GI50 values in the micromol to sub-micromol range. Especially compound 10a gave 0.026 μM to 0.035 μM GI50 for five cancer cell lines. The mechanistic studies

  设计，合成和评价了一系列新颖的查耳酮类似物作为抗癌剂。抗增殖活性测试的结果表明，大多数类似物均具有中等至非常好的抗增殖活性，GI 50值在微摩尔至亚微摩尔范围内。对于五个癌细胞系，尤其是化合物10a给出0.026μM至0.035μM的GI 50。包括微管蛋白聚合抑制，微管动力学破坏和细胞周期阻滞测定在内的机理研究表明，化合物10a可以在体外有效抑制细胞微管蛋白聚合，干扰有丝分裂，导致延长的G2 / M细胞周期停滞，并最终导致癌细胞的细胞凋亡。综上所述，这些结果表明10a可能成为开发新的抗癌药物的有前途的先导化合物。
• Efficient Method for Preparing Functionalized Benzosuberenes
  申请人：Pinney Kevin G.

  公开号：US20120130129A1

  公开（公告）日：2012-05-24

  The disclosed process can efficiently synthesize functionalized benzosuberenes. The process provides an improved method of production of benzosuberene and compounds containing a benzosuberene moiety, which is characterized by a ring closing methodology comprising reaction of a 5-phenylpentanoic acid with Eaton's reagent to form the benzosuberone. The process, optionally, further includes steps for adding a functional group at the ketone position.

  揭示的过程可以高效合成官能化苯并戊二烯。该过程提供了一种改进的苯并戊二烯及含有苯并戊二烯基团的化合物的生产方法，其特点是通过将5-苯基戊酸与伊顿试剂反应形成苯并苯酮的环合方法。该过程还可以包括在酮位置添加官能团的步骤。
• [EN] BENZODIAZEPINONES AS FAK INHIBITORS FOR TREATMENT OF CANCER<br/>[FR] BENZODIAZÉPINONES À TITRE D'INHIBITEURS DE FAK POUR LE TRAITEMENT DU CANCER
  申请人：ABBOTT LAB

  公开号：WO2012045194A1

  公开（公告）日：2012-04-12

  Disclosed are compounds which inhibit the activity of focal adhesion kinase, compositions containing the compounds, and methods of treating diseases during which focal adhesion kinase is expressed.

  揭示了抑制细胞焦点粘附激酶活性的化合物，包含这些化合物的组合物，以及治疗焦点粘附激酶表达相关疾病的方法。

表征谱图